Quantum-Si Incorporated: Business Overview, Financials & Competitive Analysis
Quantum-Si Incorporated scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage proteomics innovator with transformative technology but elevated execution and commercialization risk as it scales from R&D to revenue generation. Quantum-Si shows promising technology and expanding revenue (182% YoY growth in 2024), but operates at significant losses (-$101M in 2024) with early market adoption. Stock performance has lagged broader biotech.
What is Quantum-Si Incorporated's industry? Quantum-Si Incorporated (quantum-si.com) operates in Life Sciences Tools & Diagnostics / Proteomics. AskCyborg classifies Quantum-Si Incorporated under Life Sciences Tools & Diagnostics / Proteomics in its company registry.
Quantum-Si is a life sciences company developing next-generation protein sequencing (NGPS) technology through its proprietary single-molecule detection platform. The company commercializes benchtop Platinum instrument...
Cyborg Score thesis
Early-stage proteomics innovator with transformative technology but elevated execution and commercialization risk as it scales...
Read the full analyst-debate transcript →Get the Latest Quantum-Si Incorporated Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeQuantum-Si Incorporated Overview
Pro stress-test →Quantum-Si is a life sciences company developing next-generation protein sequencing (NGPS) technology through its proprietary single-molecule detection platform. The company commercializes benchtop Platinum instruments and consumables that enable researchers to perform protein analysis with unprecedented resolution and streamlined workflows.
Strategic Profile
Pro stress-test →Quantum-Si targets the expanding proteomics market by replacing traditional, multistep mass spectrometry workflows with direct single-molecule protein sequencing. The company leverages proprietary semiconductor chip technology based on time-domain sequencing to position itself as a high-resolution alternative in antibody characterization, biomarker identification, and protein variant analysis.
Competitive Landscape
Pro stress-test →Quantum-Si competes in the proteomics and life sciences tools market against established sequencing platforms and mass spectrometry vendors. Key competitive references include Pacific Biosciences (PACB) in sequencing and other protein analysis platforms. The company differentiates through single-molecule detection resolution and streamlined workflows, targeting research and translational laboratory markets seeking alternatives to legacy mass spectrometry approaches.
Industry Context
Quantum-Si Incorporated operates in Life Sciences Tools & Diagnostics / Proteomics.
Key facts
Founded: 2013 · Headquarters: Branford, Connecticut, US · Revenue: $3.06M (2024)